Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

doctor examines patient data on their tablet

TAVR technology keeps evolving, improving outcomes without compromising valve performance

Sponsored by Medtronic

TAVR is a go-to treatment for symptomatic severe aortic stenosis in much of the world, thanks in large part to the hard work of research teams that never stop looking for new, innovative ways to make the technology more effective.

Medtronic_Coronary access

Q&A: How supra-annular, self-expanding TAVR valves open up options for future interventions

Sponsored by Medtronic

TAVR procedures have surged more than 30% since 2020, with more than 107,000 patients receiving a new prosthetic valve in 2023 alone. As this trend continues, it’s increasingly important that cardiologists consider the long-term impact on future coronary interventions patients may need.  

Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.

Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Daniel Judge, MD, director of the cardiovascular genetics program, Medical University of South Carolina, the Edwin W. and Teresa H. Rogers Endowed Chair for Cardiovascular Research, Medical University of South Carolina, presented the results of the late-breaking ATTRibute-CM study for the drug acoramidis used to treat transthyretin amyloidosis at AHA 2024.

ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data

Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.

SCAI celebrated William W. O'Neill, MD, and Cindy L. Grines, MD, two veteran interventional cardiologists who played key roles guiding the development of primary percutaneous coronary intervention (PCI) as a treatment for ST-elevated myocardial infarction (STEMI) patients.

Cardiologists reflect on developing primary PCI in face of criticism and pushback

SCAI celebrated cardiologists William W. O'Neill, MD, and Cindy L. Grines, MD, for the important roles they played in the development of primary PCI. “It was challenging,” Grines explained. “We had the pharmaceutical industry that was anti-primary angioplasty and we had a lot of our own colleagues that were anti-primary angioplasty."

bicuspid aortic valve disease TAVR

How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS

Self-expanding and balloon-expandable TAVR valves are associated with comparable success rates and one-year outcomes when treating type 1 bicuspid aortic stenosis. However, each valve type comes with its own advantages and disadvantages.

Thumbnail

Asante Medical facing $488M in lawsuits after fentanyl diversion linked to 16 deaths

The nurse responsible has been charged with 44 counts of second-degree assault. Her criminal trial begins Dec. 30.

The rapid rise of artificial intelligence (AI) has helped cardiologists, radiologists, nurses and other healthcare providers embrace precision medicine in a way that ensures more heart patients are receiving personalized care.

FDA clears AI screening tool for cardiac amyloidosis

Ultromics designed EchoGo Amyloidosis to evaluate routine echocardiogram results for signs of cardiac amyloidosis. It received the FDA's breakthrough device designation back in 2023.